{
  "bio": [
    "In 2005, Andreas Struengmann and twin brother Thomas sold their generic drugmaker Hexal (plus a stake in Eon Labs) to Novartis for some $7 billion.",
    "They cofounded Hexal in 1986. The company launched the highly successful cholesterol-lowering drug simvastatin, a substitute for Merck's ZOCOR.",
    "The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.",
    "Their portfolio includes Germany's BioNTech and Uruguay's Mega Pharma, initially a joint venture with Argentine billionaire Alberto Roemmers.",
    "In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann."
  ],
  "about": [
    "The coronavirus vaccine developed by BioNTech and its partner Pfizer was the first to receive emergency use authorization from the U.S. Food and Drug Administration.",
    "After studying medicine in Freiburg, Germany, Andreas worked as a doctor in South Africa."
  ]
}